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I~TRODUCTION 
There are several reasons why an examination of the im-
pacts of trademarks in the pharmaceutical industry on 
the developing countries is opportune. First, the nature 
of supply and consumption is strongly conditioned by the 
trademark system. Second, the pharmaceutical sector is 
the most importantinternatlonally as far as the regis-
tration of trademarks is concerned - what happens here 
has a powerful influence elsewhere. Third, an interna-
tionally recognised alternative to brand names 1 as an 
identification method, namely the use of generic names, 
exists and is in fact used to varying degrees by differ-
ent countries •. This implies that policies which wished 
in any way to restrict the role Cif trademarks could be 
constructed upon a solid foundation. Fourth, very few 
industries exhibit the compelling social significance 
which is a hallmark of pharmaceuticals and few involve 
the complex pattern of relations associated with the 
industry. Medical doctors, pharmacists, individuals as 
patients, the social services, and the large chemical 
groups are all· intimately concerned with the directions 
this industry.hastaken and might taKe in the future. 
As an introduction which simultaneously confronts the 
reader with several of the bedrock issues, the following 
paragraphs elaborate briefly the four reasons for in~er­
est that have 'just been given. 
The value of drug production in 1971 has beenesti-
mated at approximately $21 billion (excluding the social-
ist countries of Eastern Europe and China - important 
exceptions since they may be significant sources of sup-
ply for several generic drugs). About 10 per cent of 
this output was produced in developing countries, with 
a high concentration in India, Brazil, and Mexico which 
accounted for some 56 per cent of the developing country 
total. 2 Though developing countries have some 70 per 
cent of the world's population they account for only 20 
per cent of world consumption3 with per capita figures 
probably ··not in excess of .$5 in Latin America and per-
haps between $1 and $2 in Asia and Africa. Yet, due to 
the highly unequal distribution of income, this cons~p­
tion corresponds to limited segments of the population 
only - the HathiCommittee in India estimated that only 
around 20 percent of the Indian population uses ,modern 
drugs. 4 -
The number of oroducts, and still more the variety 
of presentations under which they are sold, is very high 
in almost all countries. Statistics on the number of 
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presentations indicate that in Belgium there' were 9,000 
on the market; in France 8,500; in Federal Germany 
24,000; in Italy 21,000; in Spain 12,400; in the UK 
9,000;lntheUSA anywhere between 14,000 and '35,000; 
and in'developingcountries, Brazil 14,000; Coloinbia 
",15,000; India 15,000; and it has been said that in 
Mexico there may be as many as 80,000 f:tems on the mar;" 
ket.S.' Given the striking degree of,productdifferentia-
tion, it is scarcely 'surprising that promotion costs as 
a proportion of sales are also high, usually accounting 
for at least one-gixth and sometimes greater thaI). one-
quarter of sales. The costs of ppomotion apeweZZ in 
excess of those fo~ peseapch and deveZopment. often by 
a factop of 3 op mope: above aZZ eZse phapmaceuticaZs 
is a mapketing intensive industpy. ' 
Studies in various countries ,have underlined the 
pivotal role played by the pharmaceutical sector as a 
user of the trademark system. Thus a study of Ethiopia 
found that around one-third of all trademarks registered 
were in pharmaceuticals;7 an analysis of 845 contracts 
deposited with the National Register of Contracts for 
the Licence and Transfer of Technology 'in' Apgentina in 
1972 and ,involving trademarks (either alone or linked 
with patents and technical assis'tance) showed that phar-
maceuticals was a dominant sector;8 for Mexico an exani-
ination of a sample of '618 contracts containing trade-
marks and accepted for registration by the government-
between 1 February '1973 and 31 Deceinber 1975 showed 
pharmaceuticals as one of the principal industrial 
branches involved;9 while in IpeZand calculations based 
on the international (Nice) classification of trademarks' 
demonstrated -that " " 
on average, registrations 'for, t.hechemicalclasses 
1-5 together make, up about 40 per cent of the total 
registration each year. This is over twice the 
number coming forward from any other identifiable 
industry grouping (e.g. engineering ciasses 6-12 
include only 15-18 per cent of registrations). 
Even food, drink and tobacco taken together-do not 
produce more than about 20 per cent of annual reg~ 
istrations. Taking individual clas'ses, the number 
of registrations in Class 5, which includes'phar-
maceutical substances, has consistently been the 
'largest with a comfortable margin over the next 
biggest class ••• Trademarks in the pharmaceuticai 
class appear'to be uniquely important. The ,sheer 
numbers of ,applications to register in Irelandfoi: 
Class 5 far outweigh those for any other class,-
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they generally account for around 20 per cent of 
the total number in anyone year. IO 
In any field generic names, Le. word~ or phrases 
which describe objects of a particular kind, either ac-
quire the status of 'standard words' through repeated 
and familiar usage, or are created expressly to serve 
that purpose - it is the latter which has occurred with 
pharmaceuticals. Drugs can be defined by a chemical 
name consonant with standard nomenclature in chemistry: 
in many instances, however, the resulting names are very 
long and involved. With the increase in numbers and 
complexity of drugs, names simpler than the chemical ones 
were adopted and included in national pharmacopoeias, 
such as those of the UK and the USA. International dis-
tribution of drugs, hO~lever, resulted in a situation 
where different names were employed in differentcoun-
tries, a 'situation both confusing and potentially dan-
gerous. The World Health Organisation was thus reques-
ted to assist in the establishment of a list of accept~ 
able 'International Non-Proprietary Names' ..., this has 
been done and is adopted by most countries and quoted 
in the national pharmacopoeias. It is these ~on-propri­
it~ry names whiah are known as generia names and the 
drugs sold under these names as generia drugs; fairly 
well known examples are tetracycline, chloramphenicol 
and diazepam. It is against this background that brand 
names in the pharmaceutical field must be seen, for 
whereas. the laboratories were the ones whose work. prov-
ided the basis for the selection of generic names, they 
also invented the brand names. Solomon Garb, professor 
of pharmacology at the· Albany Medical College, giving 
evidence before the Kefauver Committee, had this to say 
about the origin of generic names: Not only are the ge-
neria names areations of drug aompanies themselves, but 
aft~r making them aomplex andunp~onoundeable, these 
same aompanies prdaeed toaite their aomplexity as an 
argument for the use of their simple trade names. II 
Thus the confusion which the generic names were origi-
nally intended to eliminate has been re-introduced on a 
greatly amplified scale via the proliferation of trade-
mark names. As Walter Modell, editor of the Journal 
Cliniaal ·Pharmaaology and Therapeutias observed during 
the Kefauver Committee hearings: . 
Trademark names often introduce confusion· in an al-
ready difficult and complex subject by providing 
more than one name for the very same drug. Some-
times there are as many as 25 p~oprietaiy synonyms 
which have been created for the non-propr.ietary 
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names of drugs they use. Thus, it is possible in a 
discussion between two- specialists in the same -field 
for neither to know that each is talking about the 
same drug. -Imagine the dilemma this can create for 
the_ less expert, tpe student and the general prac-
titioners.12 
The modern pharmaceutical industry is a compara-
tively recent phenomenon: 
The big chemical groups have become interested in 
the pharmaceutical industry mainly since the 1930s 
when the active ingredients began to be manufac-
tured more and more from synthetic substances and 
less and less from substances of vegetable or ani-
mal origin. Similarly, industries with experience 
in fermentation were led into involvement with the 
pharmaceutical industry following the discovery of 
the antibiotics and their use- in the 1940s. 13 
During the same period a dramatic change occurred re-
garding purchase of medicaments - in several countries 
the State is the major buyer, with its payments being 
in part financed by workers' contributions to social 
insurance schemes. There is thus a peculiar market sit-
uation where the decision maker (the-doctor) is distinct 
from the user (the patient) who in turn is not the one 
who directly meets the bill. 14 Thus the usual mechan-
isms encouraging economy are not present whilst public-
ity is directed far more at the doctor than the user. 
Both the direct and indirect costs inherent in this sit-
uation have their implications for health policy asa 
whole. Expenditure on drugs represents around 10 per 
cent of total health care disbursements in an average 
industrialised country but may be _of the order of IS to 
20 per cent in a developing country - what could be 
saved on drugs could be a valuable injection-elsewhere 
in the system._ 
Shifts in-the pattern of supply and purchase have 
_been accompanied by major -changes in the -roles played 
by various professional and other groups. 
It is a commonplace that the tasks that the pharma-
cist is called upon to undertake have changed dra-
matically over the past quarter century. From be-
ing-a craftsman who made medicines, the pharmacist 
has become a distributor of medicines made by man-
ufacturers. 1S -
The squeeze on the pharmacist is in sharp contrast 
to the internationalisation of the guild type organisa-
tion which defends the interests of doctors. As the 
medical hierarchy has become more pronounced, so the 
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corporations producing pharmaceuticals have devoted ever 
more resources to coaxing the UpPer echelon ,of that hi-
erarchy into :buying the' brand name drugs. Since, as I 
will stress again later, the training doctors receive 
(both during and after qualification)is woefully weak 
regarding pharmaceuticals, the publicity of the corpora-
tions tends to be the decisive factor influencing pre-
scribing 'habits. Despite the large number of firms en~ 
gaged in pharmaceutical production in most countries, 
the demand is met by a small percentage of corporations 
who are much the same from place to place. Thus, al-
though roughly 5,000 companies are registered for phar-
maceutical production in the OECD countries, some 50 
corporations (a bare one per cent of the total) account 
for 80 per cent of sales. It is the publicity emanating 
from these enterprises which is the truly powerful voice. 16 
ThIs, in broad sweeps of the brush, is the canvas 
on which trademarks appear. In the next section I dis-
cuss in more ,detail the key role of brand names in the 
sector; the third section analyses certain key policy 
initiatives taken (or proposed) qUite recently, and, in 
the light of these, looks again at some of the arguments 
advanced in 'favour of brand names. The concluding sec-
tion offers some suggestions on policies which might be 
considered ~n developing countries. 
THE IMPACT OF TRADEMARKS IN THE PHARMACEUTICAL SECTOR 
What are the' effects, direct and indirect, of the brand 
name epideinic? They may be summarise,d under the follow-
ing headings: 
1. Cost 
There are huge price differentials between products sold 
by brand names and those sold under, their generic titles. 
Lall has reported that 
The Kefauver Committee uncovered innumerable i~~ 
stances of branded products 'being sold at prices up 
to 1,000 per cent higher than others in the United 
States with no effect on the market shares held by 
the large companies. In Roche's case, a small 
British firm supplies its equivalent of Librium, 
under a compulsory licence, at prices 25 per cent 
lower than Roche but had not been able to capture 
even 3 per cent of the market for the drug by 1970; 
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._._. ~in India, LibriUILwas __ sold_~in _1972-at-Rs.···i6-.00 
(per 100'tablets of 10 mg each) when. generic ,name 
equivalents were available from small producers for 
. prices as lo~ as Rs. 1~50.17 
Likewise a study of 7 antibiotics no longer proteated 
by pat~nts in the us showed that the branded drugs were 
priced well in excess of their generic counterparts and 
that in 5 o'f the 7 cases the market was-dominated by 
.the highest priced drug. Thus 
Abbott's Erythrocin holds a 60 per cent share of 
the erythromycin market although it sells to drug-
stores for $12.96 for a hundred 250 mg tablets, 
while Sherry Pharmaceutical Company se.lls a non-
branded version for $5.70. Pfizer's Terramycin 
holds 99 per cent of the market for oxytetracycline 
even though drugstores pay $18.10 for a hundred 
250 mg capsules, while they could get it throu~h 
smaller manufacturers for as little as $1.90. 1 
Recounting the experience of the State Pharmaceu-
ticals Corporation of Sri Lanka, Bibile shows that in 
1972 'the private sector imported 23 brands of tetra-
cycline at an average price of $16.92 per 1,000 capsules. 
By 'shopping around' the Corporation pu~chased tetra-
cycline at $6.33 after considering 45 offers. ,19 Even 
among the brand name articles there are considerable 
differences in price across countries; 'recent data show 
that Libriurn and Valium are at present sold to different 
developed countries at price differences of nearly 600 
to 1,000 per cent. ,20 There .dan be no doubt that restria-
tion of legal drug sales to generia items, and the pur-
ahaseof these through bulk buying agenaies, would result 
in substantial savings of foreign exahange for the devel-
oping aountries. partiaularly if joint purahasing aould 
be effeated by the smalZer deveZoping aountries. 
2. Distortion Of Information 
Drug sales are of two sorts, over-the-counter and on pre-
scription from a physician (the 'ethical' drug. sales) • 
Since medical doctors are not systematically subjected 
to post~university training dealing with new products 
and tl:\eir therap~autic value, pharmaceutical 'compa:nies 
become the major source o'f knowledge. While they do 
provide some information about their-products which is 
genuinely valuable, this is mixed with a high .content 
both of misleadinginfo~ation and 'failuret~ provide 




The publicity effort has been described as 
The object is to make a lasting impression on the 
memory of the doctor, who only knows about.SO to 
200 medicines, depending on his special line. A 
more specific goal is to bring t~e physician to 
prescribe a given brand name rather than the cor-
responding generic name, since several companies 
may sell a given drug under different brand names 
and the drug maybe sold under.its generic name as 
well, at a far lower price. 21 . . 
The diseases for which the.drug is recommended are 
known as its indiaations; and conversely, those against 
which it should not be used are called its aontra-indi-
aations. 
The extent of a drug's indications is no academic 
question. If, for example, a drug is recommended 
and used for a disease against which it is not 
effective, then the disea~e, perhaps serious, will 
be left untreated. In 'addition, and despite the 
ineffectiveness of the drug, the person using it 
still runs 'the risk of its toxic effects. Even if 
the drug is effective, the person may be subjected 
to unnecessary risks if a less toxic drug would do 
the job as well. 22 . 
It has been noted that in Brazil, for example, Ambra-
Sinto, a combination of chloramphenicol and tetracycline, 
was, according to the package insert, recommended for 
more than SO. different conditions. Ledogar .has stres-
sed that the foreign marketing practices of us. pharma-
ceutical transnationals in Latin America are open to 
severe criticism on this score. 'Just as mahu·facturers 
are often quick to recommend a drug fora new indica~ . 
tion, they can be very slow to modify .or remove outdat-
ed indica:tions from their foreign labelling and promo,:," 
tion. '23 
Doctor Maria Dolores Torres Pons estimates that 7 
out of 10 prescriptions in .Spain maybe erroneous on 
account ()f the distortion in supply of information and 
the inadequacy of the pharmalogical training. ofdocitors 
t9 cope with the biases. She says: . 
From the discovery of penicillin to the present 
day, an infinite n~er of antibiotic products have 
been . isolated .. and synthesized eve~ though many of 
them have. had to be. rejected because they are toxic 
o~ ineffective. Nevertheless, this great prolifer-
.. ation 9f substances has brought with it such a con-
fusion that the utilisation of antibiotics, at 
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least in hospitals, may not be adequate, sometimes 
because they are, admini!;tered in excess and'bn"-
other occasions because their use is unjustified ••• 
To all qualified personnel, but, most especially to 
doctors, propaganda concerning the d~stinct pharma-
ceutical preparations and forms that invade the 
market arrive constantly.24 , : 
Thus the information provided by the drug companies 
meets very low standards of objectivity due to ,the need 
to stimulate sales of brand name products; doctors are 
not trained to assess pharmacological data on a regular 
and reliable basis; and there is' a dreadful lack o,f of-
ficial provision of information on drugs. These depres-
sing and dangerous features of the market are present 
both in developed and develoPin~ countries, but of much 
greater severity in the latter. 5 
3. Habit Creation 
Without question the purpose of the whole advertising 
exercise is to convince the doctors of the importance 
of prescribing the brand namediug. 26 Their resistance 
to change has been concisely described by the UK'Monop-
olies Commission: , ' 
Doc,tors become accustomed to prescribing a drug 
under the brand name by which it has been intro-
duced to them by the innovator. They are not easily 
persuaded to prescribe under a different brand name; 
few of them will do so before the drug is felt to 
have been well-established for some, considerable 
time, and in practice this may mean not before ,the 
patent has expired. 27 ' " 
In fact the, sugge~tion that practices'will ,alter when 
the patent lapses is probably optimistic since the brand 
name will remain in force as will the selling apparatus 
that goes with it. 
The consequences of habit formation at the doctor 
level were thrown into sharp relie~ by Wickremasinghe 
and Bibile in their report which led to the creation'of 
the State Pharmaceuticals Corporation in Sri Lanka. 
They pointed out that 
Tetre'x, Tetracyn, Tetrarco, Hostacycline, Upcycline, 
Ambranlycin, Proba'cycline, Achromycin, Hcycline are 
all trade names under which the antibiotic teta-
cycline is available. A patient with a prescrip-
tion for Achromycin' will go from one chemist to 
another and be told that the drug is out ,of stock 
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whereas the chemist would have the same drug under 
other brand names. One patient had a prescription 
for pentazocine under one of its trade names ~ 
Fortral. Since pentrazocine is not sold in this 
country as Fortral, a speciaL user's Licence was 
obtained and the drug airLifted to find that pen-
tazocine had been avaiLabLe aLL the whiLe under 
the trade name of Sosegon. manufactured by the same 
company which seLLs it under. the name of FortraL in 
other countries. 28 . 
··Habits built up at the doctor level carryover to 
patients, on the one hand, and local producingfirnts 
(if any) on the other. The patient retains the brand 
name and if, in future, he has the same complaint and 
can purchase without prescription, the chances are he 
will ask for the trademark product he used originally. 
In her study of Egypt, Handoussa stressed that even when 
licence contracts with transnationals had terminated and 
it was possible to manufacture a product.under any name 
whatever, including the generic name, 'local firms choose 
brand names that are as close as possible to the origi~ 
nal foreign brand name,.29 A mythology has been woven 
around the name to such a degree that doctors, patients 
and domestic producing enterprises cease to act as in-
dependent decision-making agents but instead follow 
blindly the verbal sign-posts laid out with such ease 
by the name makers. Aries reports that the Institut 
Pierre Bessis in France tried to find out what's .in a 
name. 
In a study of a sampling of the French population 
they discovered, for instance, that medicines end-
ing in 'il' were regarded as modern and for brief 
mild illness. Medicines ending in '01' were·old-
fashioned, not very potent and for mild illness. 
Medicines ending in 'al' are also old, but they 
are strong and .for serious illness. l-ledicines end-
ing in 'ian' and 'an' are modern and potent.30 
.To have· created s~ch a picture speaks volumes for the 
advertising skills of the pharmaceutical companies, yet 
its implications are hardly conducive to the welfare of . 
the developing countries. 
4. WastefuL Advertising 
Wherever modern drugs are sold, an extraordinary array 
of selling devices is used, ranging from medical repre-
sentatives, to free samples, to literature of all kinds, 
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to business gifts, to sponsored conferences,. to medical 
--journa:ls"in -effect--cont'roned by-tnEl companies";" to ••• 
and the list could go -on. Seriator Kennedy described the 
situation in the USA as follows: 'What we have. is a sys-
tem of hard sell, rather than a system of objective in-
formation dissemination~ we have salesmen instead of ana-
lysts, we have the tools of selling - ginunicks, gifts, 
bonus deals - rather than the tools of science and medi-
cine - comparative information, analysis of risks and 
benefi ts of competing products. dH The medical repre-
sentatives are the key figures in this network and. the 
most expensive el.ement in the advertising budget. . 
There are 9,000 of these in France and. 8,000 in 
Federal Germany and Italy, 1,700 in Belgium. Their 
function is to call on the doctor in his consulting 
room or hospital, to explain the merits of the medi-
cines presented, to hand him printed literature, . 
free samples on request, and business gifts. In 
France such a representative, on average, 'meets ·160 
to 180 doctors per month, gives to each one 1.25 
medicines and mentions 2.6. The cost per visit is 
between Fr.Fr. 60 and Fr.Fr. 100. General practi-
tioners receive 27 representatives per month and 
specialists 14. 32 . 
A Brazilian legislator, Senator Ferreira, who is himself 
a doctor, recently conducted his own survey of the plague 
of salesmen: 
He was visted on 18 of the 21 days by a total of 69 
salesmen. He was given 452 free samples of drugs 
(after refusing extra quantities so as not to dis-
tort the counting)~ he received 25 gi~~S, including 
coffee-pots, notebooks, plastic bags. 
The use of free samples is rampant. When given to 
doctors the quantities are alIllost always sub-clinical,. 
i.e. sufficient to start but not to sustain treatment. 
They serve to imprint the name in the mind of the doctor 
and serve as an indirect source of income for him. In 
the USA· . 
several witnesses testified that it .. Tas not uncom-
mon for recipients to swap these samples at their 
local pharmacies for other items, sometimes for 
their personal use. And it.was also testified. that 
some pharmacies removed the word 'sample' from these 
products and sold them as part of their regular in-
ventory.34 
While the cash value of the samples may be negligible to 
a doctor in the USA it may not be so insignificant to a 
doctor in a developing country: yet these sampZes are 
being paid for by the purahasers of the drugs, through 
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the higher priaes aharged. 
Free samples, however, are not limited to doctors 
- they are also given to .hospitals and sometimes to 
other organisations or groups. The relevance of this 
practice was taken up by the UK Monopolies Commission 
when it examined the behaviour of Roche Products Ltd 
(the British subsidiary of Hoffmann La Roche) in its 
supply of Chlordiazepoxide and Diazepam (und~r the brand 
names of Librium and Valium) to the UK National Health 
Service. The Commission stated 
the fact that the company was able to make free 
supplies' of the reference drugs available to the 
hospital service and the armed forces also., in .the 
Department's opinion, reinforced the view that 
prices to the pharmaceutical services were too high. 
Such free ,samples, the Department said had three 
effects. First, a potential competitor would be 
discouraged since he would normally attempt to es-
tablish his initial sales in the hospital market1 
secondly, hospital doctors would prescribe Roche 
products' branded reference drugs and this prece-
dent would tend to be followed by the patient's 
general practitioner when the patient returned to 
his care1 and thirdly, hospital staff would tend 
to regard the company's products as causing the 
smallest increase in the hospital's drug bill and 
would not be so readily aware of the cost of treat-
ment of patients returned to the general practi-
tioner's care. .The Department says that, in accep-
ting the company's offer of free supplies of ref-
erence products for the hospital service and the 
armed forces, it was made clear that the Deoartment 
did not accept as fair or reasonable the company's 
refusal for an indefinite oeriod to discuss non-
hospital prices. 35 -
The quotation drives home the basic feature of the 
free sample and free supply system. It is not philan-
thropy: its purpose is to establish barriers to entry 
for aompetitors and thereby allow priaes to be higher 
'than they otherwise would be. Hence we have an extremely 
expensive, socially wasteful, advertising complex whose 
function is to restrict competition and maintain prices 
at levels way in excess of those that could prevail in 
a more rational framework. 
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5. [Y!nM~nq~. oy!.go)J~rnm~1'I.t;.pe!lisi9.~:::MC1,k,i1'l.g 
In an environment where so· much depends on certain piv-
otal groups; such as medical doctors, and certain pivo-
tal.administrative bodies, such as the Ministry of Health, 
taking decisions in favour of.particular brand name prod-
uctsrather than others, it is· scarcely surprising that 
there is heavy pressure by the companies to make sure the 
steps taken are favourable to them. Brazil and India,· 
the two developing countries where .the greatest amount 
of drug production takes place, bear ample witness to the 
pressures. 
Sources within the Brazilian parliament recently 
.called for an investigation into the compromising 
relationship between multinational pharmaceutical 
companies and the nation's drug control agencies. 
·A parliamentary investigating. committee was re-
portedly given an internal document of the Swiss 
firm Ciba-Geigy containing a list of 135 public 
officials in the SNFMF LBrazil's National Service 
for the Control of Pharmaceutical product.27 and 
other licensing agencies who were to receive small 
'gifts' and 'donations' from the company. 
In India 
one of the modi operandi is to employ highly quali-
fied and highly paid 'medical advisers' ~ brilliant 
young men who could have been the pride of their 
profession had they chosen to practise it, instead 
of seeking comparative ease and higher lucre toeing 
the line of the multinationals ••. The function of 
these 'medical advisers' seems to be. to prepare· 
literature on 'branded' drugs, arrange conference~. 
for popularising them and to liaise with government 
agencies to sell the ideas of the multinational 
firms to them. A recent report published in the 
Washington Post and reproduced in local journals 
shows how one multinational company. influenced the 
higher echelons in our government in accepting· a 
contraceptive pill. But for the publication of 
this report in a foreign Journal, this incident 
would not have seen the light of day in this coun-
try. In such matters the 'medical advisers.' play 
a significant role. This local brain drain is no 
different from the drain one often hears about when 
technical and scientific people leave this country 
in search of fortunes abroad. 37 
These direct pressures for the purchase of specific 
drugs form only part of the story. For while the compan-
ies are engaged in promoting brand name sales, to some 
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extent in competition with each other, they also. act. to-
gether to defend their joint interests in reserving the 
structure of the industry. In the UK the Sainsbury Com-
mittee, which in the middle 1960s investigated the rela-
tionship 0:1; the pharmaceutical industry with the National 
Health Service, had asked for stringent controls over the 
in~ustry's marketing practices but this was never imple-
mented. Similarly the Macgregor Committee, which had 
existed as an official body to examine the crucial ques-
tion of the effectiveness of drugs, w.as disbanded in 1970 
and no new group has been established in its place. Lang 
concludes 'All the evid.ence points to the conclusion that 
the.ABPI [the drug industry's pressure grouEl wields too 
much influence, has accumulat~d too much expertise, and 
has become too entrenched in the bureaucracy of the gov-
ernment for the elected representatives of the people to 
deal with it effectively. ,38 . 
Shortly after the publication of the Hathi Commit-
tee's report on the pharmaceutical industry in India, in 
April 1975, there were already reports of response. 
Furious lobbying had preceded, and has followed, 
the submission of the report. The· pharmaceutical 
industry - especially the powerful foreign sector 
of it - clearly has its interests at stake here .•• 
the foreign drug companies are already influencing 
the direction of the decisions by taking a tough 
stand.. While Press and Parliament will discuss the 
Hathi Committee's. policy recommendations for total 
or partial takeover of these companies, the foreign 
companies have been actiVely lobbying for the issue 
of new licences for their expansions •. Twelve ap-
plications for substantial expansion are in fact 
pending with the government 1 the drug firms seem 
confideritthat all these will be cleared in due 
course. 39 . 
Under these circumstances it seems doubtful that 
the wider implications of the brand name syndrome receive 
the consideration they deserve: it is all too easy for 
partial and biased decisions to be taken by those regu-
.larlysubjected to the bombardment of pressures from the 
small number of producers whilst the voices of the con-
sumers scarcely are to be heard. 
6. Inappropriate Consumpti.on 
When the.criter~a are those of commerce rather than pub- . 
licwelfare, and where in any. case the commercial impetus 
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involved emanates from markets whose needs are very dif-
f~:r:£:ln~_!_:r:9I1!~ho~£:l_ ()!~ .1::ll§!_ !llajo~,ij::y oJ _];It:lOIl;I._E?_:i.~ r~_c:i,p':i,~n1; 
countries, it is scarcely surprising that drugs are mal-
used. The extremely high proportion of branded to gene-
ric drugs as well as the elevated prices both operate 
against theexistance of a set of drugs relevant.tothe 
health needs of the population as a whole and available 
at prices, in quantities and at the locations in the coun-
try which will allow them to be used as required. Given. 
that the resources which can be spent on drugs are severe-
ly limited in developing countries ( and everywhere else 
for that matter) the relation between the cost of a drug 
and its clinical efficacy is of critical significance in 
determining what set of drugs should be used. A newer 
drug might have fewer possible adverse reactions than an 
older .. one but may be far more expensive. If many people 
need treatment their prospects of getting it will be 
greater if supplies are restricted to the older drug. 40 
Wickremasinghe and Bibile put the point in their 
discussion of the management of pharmaceuticals in Sri 
Lanka. 
A good example is the use of the aspirin type of 
analgesic drugs. The current consumption of this 
type of drug is 130 million tablets annually, of 
which 50 million are used ·by government hospitals 
and dispensaries and 80 million in the private sec-
tor. The 80 million is made up of 60 million tab-
lets of 'Disprin' and 20 million of aspirin, 
'Aspro', buffered aspirin, 'ASC' pink tablets and 
paracetamol. Clinical trials indicate that all 
these preparations do not have significant advan-
tages over aspirin with regard to efficacy and 
adverse reactions. Furthermore, aspirin tablets 
are far cheaper and more stable than the other 
analgesic preparations mentioned. Aspirin tablets 
will, therefore, be adequate to meet situations 
where this type of analgesic treatment is required. 
For a small number of people who cannot tolerate 
aspirin, paracetamol tablets will be required. 
Manufacture and import could therefore be restric-
ted to aspirin tablets and paracetamol tablets and 
the price to the public would be considerably re-
duced. 41 
Unfortunately the inappropriate consumption is not 
confined to that of well-established drugs. The testing 
of pharmaceuticals goes beyond the laboratory - a key part 
consists of clinical trials or, to put it bluntly, giving 
the drugs to people and watching for any unexpected ef-
fects which might be detrimental to their health. In the 
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developed countries the regulations governing this kind 
of activity are growing steadily more severe. Govern-
ments are not permitting the drugs to be given to mem-
bers of the human population until ever more stringent 
tests have been carried out beforehand. Due to the sub-
stantial differences'in laws among countries, regulations 
in practically all countries of the developing world are 
far more lax. So the corporations are shifting their 
clinical testing to the ,developing world; the laboratory 
work is performed in the industrialised countries and the 
use on humans begins in the developing world. To the 
massive bias inculcated by the social misfit nature of 
ordinary drug consumption is added the adoptl.on of devel-
oping countries, as the places where new drugs, as likely 
as not but of little relevance to the social needs of 
those countries, are first tried out. 
These six aspects of the industry: cost; distortion 
of information; habit creation;'wasteful advertising; in-
fluence on government decision-making; inappropriate con-
sumption; arise from the presence of market power as man-
ifested by the dominant members of the ruling oligopoly 
of corporations, Much attention has been given to tech-
nical knowhow as a source of this power. Whatever may 
have been the role of this knowledge some time ago, it 
has ceased to be the salient feature of the industry. 
Now it is marketing which has become the pivot on which 
relatively the heaviest expenditures are made. 'But all 
of this expenditure by the pharmaceutical company would 
be to no avail unless the doctor was able to identify 
and specify that company's product; hence the importance 
of the registered trade mark, the exclusive use of which 
is the right of that company and no other. 42 
THE POLICY CONTEXT 
It is scarcely surprising that, faced with the manifold 
difficulties described above, certain steps are being 
taken (or proposed) in at least some developing countries 
to tackle the problems. The possibilities have recently 
been given clear expression by the Non-aligned Countries, 
at the Fifth Conference of Heads of State held in Colombo 
in August 1976; Just prior to the Colombo meeting a 
Group of Experts on Pharmaceuticals had met at Georgetown 
and,on the basis of their report43 the Heads of State 
passed a ResoZution on Co-operation among DeveZoping 
Countries in the Produatiim. Proaurement' and Dist"riDution 
of PharmaaeutiaaZs.'44 In the first operative paragraph 
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of that resolution the following points, among,others, 
are 'made: 
(The Conference ••• ) 
1 Endorses the recommendations of the Group of 
Experts which met at Georgetown in July 1976 and 
':;1hich proposes among other things: ' 
(a) the preparation of a list of priority pharma-
ceutical needs of each developing country and the 
formulation of a basic model list of such needs 
as a general guideline for action by the develop~ 
ing countries; 
(b) the establishment of a national buying agency 
to undertake the purchase and supply of p~armaceu­
ticals; 
(cl the elimination, wherever possible, of brand 
names and the adoption of the generic names for 
pharmaceuticals; ,and provision of information only 
from official sources. 
These three interretated proposals form the bac~­
bone of what has happened so far and provide, the central 
elements of future measures. 
Actions in Devetoping Countries 
(il Sri Lanka45 
Modern medical services 'in Sri Lanka are provided by ,a 
state sector whose administration is under the control 
of the Department of Health Services, and a private ,sec-
tor in which medical practitioners charge fees '~or their 
services. The change wrought in the supply of pharmaceu-
ticals can be ~raced to 1959. Prior to that date,both 
public and private sectors were plagued by the costly , 
and dangerous practices described earlier in this study. 
Faced 'with the confusion and proliferation of medicines, 
the Ministry of Health published a Ceylon Hospitals For-
mulary containing a list of 500 essential drugs (in 1,000 
dosage forms) under their generic names, along with,in-
structions on the use of these drugs. From that point 
onward this list was the guide for all drugs to be used 
in hospitals. 
A severe foreign exchange crisis in 1963 provoked 
import restrictions with private sector pharmaceutical 
imports limited to an approved list of drugs which 
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contained 2,100 items (in 3,000 dosage forms) as against 
double that before, 4,000 items (in 6,000 dosage forms). 
No limits were placed on the use of brand names within 
the approved list and the .standard publicity machine was 
allowed to keep running untrammelled. A first step in 
rational ising private sector dealings had been taken, 
nevertheless, and this had been possible due to the par-
lous foreign exchange situation. Often situations of 
economic crisis, when the government as a whole is pre-
pared to examine fresh ideas, may provide the opportunity 
to present schemes whIch would otherwise not be given 
such careful consideration. 
By 1970 there were once more severe difficulties. 
Prices had risen by at least 50 per cent as compared to 
1963 levels, annual foreign exchange allocations had de-
creased, and both public and private sectors complained 
of drug shortages. Given that the government could not 
make more foreign exchange available, drugs had to be 
obtained more cheaply. An investigation into sources of 
supply showed that, had the private sector purchased 
several of its major imports at prices paid by the public 
sec~or, .it would have paid only 30 per eent of the amount 
aatuaZly disbursed. On the basis of these details, and 
of other proposals contained in the previously cited re-
port of Wickremasinghe .and Bibile, a State Pharmaceuticals 
Corporation was established in 1971 to rationalise man-
agement of pharmarceuticals in the private a·s well as the 
public sector. 
To begin with, the' number of drugs authorised for 
use by the private sector was reduced to 600 (in 1,000 
dosage forms). To achieve this there was a sharp reduc-
tion in.the number of imitative drugs, removal of an 
appreciable number of fi~ed-combination drugs which were 
not useful, arid deletion of several drugs either not pos-
sessing proven therapeutic value or having high toxicity. 
The Corporation then organised a changeover from brand 
names to generic names. The switeh has been earefuZZy 
phased to harmonise with the pUbliaation of aross-refer-
enae lists of brand and generia names. Gradual change 
is important to ensure that doctors can again begin to 
identify the generic items (after so much bombardment, 
with brand names), that reactions from the producers are 
successfully overcome, and that quality standards are 
satisfactory •. For long-established drugs it has proved 
relatively easy to introduce generic labelling; for 
others the adjustment has been slower with labelling us-
ing both the generic and the brand names but the former 
being twice the size of the latter. In this way doctors 
can learn to identify the product by the generic name 
---'-, -, --'------'----
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and the brand can be drcpped altcgether. Sri Lanka being 
a rather small cCUntry, and the necessary quantities'cf 
scme drugs bedng small, there remain some items fcr which 
it has nct 'thus far been pcssible to, use brand names since 
it is uneccncmic fcr manufacturers to, print special la .... 
bels for Sri Lanka. ' 
An active policy has been adopted by the Corporation 
to ensure that information is distributed to doctors and 
pharmacists and this is reinforced by the crucia~ aspect 
of quali'cy control. Since the Corporaticn i;; Emgaging 
in bu~k buying. with the substantial savings menticned 
earlier (including majcr price reductions by the 'trad-
iticnal' suppliers), it is vital to, guarantee the quality 
of the prcducts associated with different tenders. Ideal-
ly the Corpcraticn wculd itself undertake inspection of 
the factories of suppliers and purchase only from those 
following Good Manufacturing Practices (as established 
by the World Health Organisaticn). This type of inspec-
tion is not possible on a systematic scale (it would be 
much easier if 8evera~ deve~oping countries together ar-
rangedfor inspection by one of their representatives) 
so other procedures are used. In particular, the board 
which examines tenders can identify drugs where formula-
tion and quality are critical and ensure that such pur-
chases are made from suppliers whose quality s,tandards 
are well known. Besides this, there are the simple pro-
cedures of requiring a certificate of quality from the 
manuf,acturer and, where necessary, arranging for an ad'"" 
ditional certificate of quality issued after'inspection 
by an authorised and independent laboratory. 
At present the Corporaticn has over 300 emplcyees' 
of whom only 15 are emplcyed on sales and distribution 
(as compared to the much higher percentage devoted 'to 
these tasks in a company occupied with marketing as such) .46 
'Given the activities of the Corporation, the extensive 
promotion of products has of course collapsed (there being 
now but a single buy,er, the State) and the paraphernalia 
of free samples and the rest has likewise ceased to, be 
relevant. 
In this structure the removal of brand names has 
meshed with a total strategy whose objective throughout 
has been the rational management of the whole field of 
purchase and distribution of pharmaceuticals. Hitherto 
domestic production of pharmaceuticals remains ona small 
scale in Sri Lanka and there is anyway no entry into the 
more complex parts of the production netwcrk, for which 
a domestic basic chemicals industry is' needed. What mat-
ters is that the trademark'based system has been complete-
ly rationalised and the enormcus sccial waste cut cut. 
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(ii) India 
Three major reviews of the drug industry have ,been under-
taken since Independence: 'The first one was the Pharma-
ceutical Enquiry Committee appointed in early 1953, the 
second was the Drugs and Equipment Standards ,Committee 
known as tp.eNaskier Committee appointed in 1962 and the 
latest is the Committee on Drugs and Pharmaceutical In-
dustry known as the Hathi Committee appointed. in 1974.'47 
~llien the first of these reported to government in 1954 
it took pains to emphasise that 'only a few firms should 
'be allowed to take up the development of the same pro-
duct' and it presented a systematic argument for the 
phased move by India towards self-sufficiency in drug 
production. More than 20 years later the drug industry 
still has to import around 70 per cent of its require-
ments and even .where the transnational firms import in-
termediates they do so focussed on those as near to the 
final product as possible rather than ,as close to the 
basic chemicals as is feasible. 
The pharmaceutical industry, of which the. lion's 
share within India belongs to the transnationals, has 
resisted proposals for change with impressive success. 
Fifty-five per cent of the business of the transnationals 
is in formulations and it has been stated that the for-
eign enterprises have 
introduced many formulations in the market which 
this poor country could well do without ••• many ir-
rational formulations particularly in the field of 
Vitamins, corticosteroids and antihistamines, fetch-
ing high prices, are alsQ marketed ••• The thera-
peuticfield has been so much 'polluted' today that 
unless some drastic measures ,are taken the drug 
industry is bound to play on the gullibility of 
patients and physicians alike. 48 
According to recent comments the public sector pol-
icies,have in practice resounded to the benefit of these 
companies. , 
A case in point is Hindustan Antibiotics (HAL), the 
public, sector unit manufacturing penicillin and 
streptomycin. The eighteenth report of the Commit-
tee ,on Public Undertakings (Fifth Lok Sabha) brings 
out how the company has deliberately restricted its 
own production of formulations so as to sell a 
large proportion of its output in bulk form to pri-
vate companies, 'even though it is more profitable 
for HAL to sell its output as formulations than in 
bulk form ••. The policy of selling a large part 
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of its output of antip~otics in bulk form~w~s pur-
sued by HAL even though this meant keeping idle 
much of its own vialling, capsuling and tab letting 
capacity. 49 ~ 
The closing remarks of the report are revealing: 
The Committee are constrained to conclude that by 
showing excessive concern for the requirements of 
private viallers and by keeping HAL's formulation~ 
capacityunderutilised all through this~period, 
the administrative Ministry as well as HAL have 
not acted as the guardian and promoter of the in-
terest of the public sector but have rather helped 
the private firms, particularly the foreign firms, 
to earn huge profits at the expense of the public 
sector and national interest. 50 
The purpose of these observations is to show that, 
at least in the Indian context, awareness of difficulties 
extends over a lengthy period and proposals have been 
offered at regular intervals. Thus far resistance has 
been strong, however, and it remains to be seen what will 
be the final fate of the Hathi Committee proposals. That 
Committee examined the brand name question in great de-
tail and it is worth repeating in full the views of the 
Committee since they unite the issues raised in this 
study: ~ 
Substitution of b~and names of d~ugs by gene~ie 
names 
The qUestion of generic names and brand names was 
extensively discussed. All facets of the problem, 
such as impact on drug prices, bio-availability, 
quality of drugs, enforcement of drug control, 
multiple ingredient preparations,~export of drugs, 
labelling difficulties, impact on small-scale in-
dustry, patent rights, distribution system, accep-
tance by the medical profession, role of distribu-
tions and pharma,cists, effect on the growth ~ of 
pharmaceutical industry, difficulties and inconven-
ience in the use of tongue-twisting generic names, 
etc, were discussed in detail. After taking into 
account ~~ all these very intricate problems, the 
Panel makes the following recommendations: 
(a) Brand names should be abolished in a phased 
manner. This step is in the right direction for 
both the rational practice of medicine and general 
national interest. Drugs which are exported may 
be allowed to bear brand names. 
(b) A beginning should be made for a changeover to 
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generic names for the drugs mentioned in Appendix II. 
These drugs are used very extensively arid their ge-
neric names are as elegant as brand names. These 
drugs should, therefore, not be allowed to be mar-
keted under brand names with immediate effect. 
(c) The changeover from brand names to ge~eric names 
may result in the increase of. spurious and substan-
d·ard drugs. It is, therefore, strongly recommended 
that steps should be taken to ensure more rigid and 
uniform quality control throughout the country. 
(d) All supplies of single ingredient drugs and 
drugs included in Indian Pharmacopoeia for Genera~ 
and State GOVernment Institutions. and Loca~ Bodies 
should. be tendered and supplies made under generic 
names. At present, drugs, though tendered under ge-
neric names, are supplied under brand names, and 
this should be· discouraged. 
(e) All drugs other than those listed in Appendix II; 
should bear labels displaying prominently generic 
names. Brand names may be mentioned in brackets. 
(f) The Drugs Controller (India) be requested not to 
give recognition to the brand names of new drugs 
w~en first introduced in this country. 
(g) Multiple drug combinations often containing 
drugs, particularly vitamins in amount far. in excess 
of what is reguiredare presently marketed in India. 
The majority of such combinations are irrational. 
There is a colossal national wastage of drugs be-
cause of such combinations. The Panel therefore 
strongly recommends that the Drug Control. Adminis-
tration should immediately go into the various drug 
combinations and take prompt meas~es·to eliminate 
irrational drug combinations. No firm shoUld be 
allowed to. import excessive quantities of any drug 
over and above what is required to go into the for.-
mulations for therapeutic and prophylactic purposes. 
(h) The Indian·Pharmacopoeia Committee be approached 
to devise simple, short and suitable non-proprietary 
names for drugs'l'lhich have long and difficult gene-
ric names. 
(i) Bio-availability studies are important in the 
case of 'a· few drugs, although this factor has re-
cently been overplayed, not always on a rational 
basis. The Panel recommends that facilities .should 
be created in different parts of the country, so 
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that the industry, both large and small-scale, can 
-take : advantage·· of suchfaci:lities to·plan··and con-
duct bio-availability and pharmacokineticstudies. 
(j) In order to keep the med:l.cal profession, partic-
ularly the general practititioners, well-informed 
about New Drugs and also to popularize the generic 
names, it is essential to take steps immediately to: 
(i) revise the Indian National Formulary: 
(ii) to publish journals on the lines of the Pre-
scribers' Journals UK, !>!edical Letter USA, or Form-
ulary Notes· of Sri Lanka. Such publications will 
have to be under the control of an Editorial Board 
comprising leaders of the medical profession in the 
country constituted by the Ministry of Health, 
Government of India. 51 -.. 
Since these recommendations raise all of thE! rele-
vant matters connected with a switch from brand names 
in this industry, some brief annotations on .several of 
the points will serve to crystallise the arguments. 
(1) Quality: Certainly every effort must be made to en-
sure that good quality products are the only ones sold. 
A large developing cou.ntry, such as' India, with a con-
siderable industrial base and numerous highly skilled 
personnel, has at least as much a chance as most indus-
trial countries to conduct quality controls - measures 
in smaller countries have already been mentioned' with 
regard to Sri Lanka. Most important, however, the ques-
tion of qua"l>ity shouZd not be confused with that of 
brand names; whiZst the protagonists of the system have 
continuaZZy propounded the inseparabiZity of the two. 
the reaZities are otherwise. 
The study of antibiotics in the US market, mentioned 
earlier, 'notes that during the tetrocycline antitrust 
case, Lederle revealed that its quality-control costs 
on a hundred 250 mg capsules of Achromycin were 1.4 cents. 
At the time, it was selling the drug, its brand of tet-
rocycline, for $3.60 for a hundred 250 mg capsules. ,52 
This means that the company's quaZity controZ' costs ac-
counted for Zes.s than 0.05 per cent of its seZling.price 
- those· who paid for the brand were.certainly not paying 
for quality control costs. In terms of a direct 'com-
parison between brand name and generic drugs, ·there is 
similarly nothing to suggest that the former. are better 
on quality: 'a review undertaken between 1966 and 1969' 
by the National Academy of Sciences - National Research 
Council [a private US organisation supported by industr~ 
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on behalf of the US Food and Drug· Administration found 
that 8.8 per cent of the 2,000 brand name drugs in the 
sample were ineffective while the comparable figure for 
generic drugs was 7.7 per cent. '53 
To summarise: good quality control is essential, 
generic drugs are at least as good on quality as the 
branded items, and the former are far cheaper. 
(2) Spurious and Substandard Drugs: The argument that 
there will be more of these under a generic than under 
a brand name system is utterly false, unless of course 
there should be marketing of spurious items as a delib-
erate policy' on the part of some manufacturers to under-
mine the generic name approach. Spurious or counterfeit 
drugs are marketed for reasons of profitability - and 
there are many. more profit opportunities with brand names. 
Hence the risks are higher ina brand name aontext. The 
Hathi Committee itself stated: 'scrutiny of the total 
number of substandard, misbranded and spurious products 
reported ••. will reveal that there are more instances of 
branded products being misbranded or spurious. There 
have been no instances where a product marketed under 
generic name has ever been reported to be spurious. ,54 
Similarly Illich, referring to work by Margaret Krieg 
in the US, says that she 
reports and proves that an increasing percentage 
of articles sold by legitimate professional phar-
macies are inert counterfeit drugs which are in-
distinguishable in packaging and presentation from 
the trade-mark produat. Detection is increasingly 
difficult and prosecution of the Mafia behind this 
black market is beyond the control of current law~ 
enforcement agencies. 55 
(3) Bio-avaiZabiUty: Drugs which are "generically the 
same can differ somewhat in their clinical effects and 
thus in their therapeutic value. The rate of release of 
the therapeutic agent maybe 'too much, too fast', in 
which case the recipient is exposed to the risk of ad-
verse toxic effects, or 'too little, too slowly', when 
the plasma concentration fails to reach the levels at 
which therapy occurs and the drug is simply ineffective. 
A recent study56 has argued that the plasma concentra-
tions just mentioned can be affected considerably by the 
methods of formulation and manufacture of the substance, 
that the brand name identifies just what method is used 
for turning the drug (active ingredient) into that manu-
facturer's medicine, that the risks of switching from 
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one brand to another may be significant, and that these 
conside:rationsare vital, in-accurate,-prescribing~ A, 
list of 43, drugs subject' to bio-av:ailability problems 'is 
given in the study. " , 
In assessing the weight of these arguments, the fol-
lowing points need to be borne in mind. First, absorp-:-, 
tiveresponse depends on the patient as well as the drug 
and there is nothing in the bio-availabili ty argument to 
suppose that any drugs are going to reach the patient 
'custom made'. Second, there may be variations as betw~en 
different batches of the same brand nainedrug.: _Third~ 
and most important, the empirical relevance of .the phe,... 
nomenon is not great. Thus, 'as evidence from the United 
Kingdom and the United States shows, there, are only a ' 
few drugs L42 noted in the United Kingdom and 24 in the 
Onited State2J where bio-avail'abil'ity presents a real nied-
ical problem. ,57 The principal cases of bio-availability 
are by now well-known and allowance for them can ,be 
e·as.ily made; given the other issues involved, it would 
be gravely misplaced policy for a developing country to 
maintain trademarks in pharmaceuticals on the g·rounds of 
bio-availability.58 
(4) Use of Generic and Brand Labe~s: The printing of 
brand labels in brackets at the side of generic names 
may be insufficient to ensure that it is gradually the 
generic name which comes to be identified. Size of let-
ters, colours used for the different words, type of print 
and even positioning of the letters are all devices by 
which the impac't of one name can be enhanced relative' to 
the other. These appear as small details, no doubt, yet 
they may influence the speed 'and precision by which doc'" 
tors come to recognise the generic names., 
(5) SimpLification of Generic names: The introduction to 
this study emphasised that it was the pharmaceutical.' in-
dustry itself which had generated both the generic and 
brand names. There may be grounds, in some instances" 
for simplification of the generic name though great ,care 
should be taken with such a propo.!'lal lest it create op-
portunities for manufacturers. to sow still further con,... 
fusion. 59 
(6) IdentifiabiZity of Manufacturer: From the buyer'·s 
point of view the important consideration is to be able 
to have recourse to the seller in the event of. either 
difficulties with 'the product or a desire tore"'order 
the same item. Publication of the manufacturer's name· 
on flasks, packets and other containers is not necessary 
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fer these purpeses since the nermal transactiens between 
buyer and seller 'effer sufficiellt indicatiens,particu-
larly at the whelesale level, er erigin (especially 
where, as has been dene in Sri Lanka, the supplier must 
give a certificate ef quality). To. retain the manufac-
ture's signet enhances the risk that purchasing patterns, 
espec;:ially by the private secter will net be amended. 
(7) S~pp~y of Information: The Hathi Cemmitteementiene4 
seme ef the seurces ef reliable infermation, beth frem 
develeped and develeping' ceuntries I there is no, shortage 
Of materia~ based on scientific rather than commercia~ 
criteria and thus no reason why even a deve~oping country 
unab~e to pub~ish its own journaZ shou~d ~ack up-to-date 
ana~yses. ' 
(8) Exports: In its cemment en this subject the Cemmittee 
maintained a flexible pesitien. As a general rule, under-
lined by the meves tewards ce-eperatien ameng develeping 
ceuntries in this area, each ceuntry sheuld refrain frem 
experting, the preblem to. ethers, i.e. augmenting the 
severity,ef ebstacles to. centrel elsewhere by adding to. 
the number ef brands to. be dealt with. If each ceuntry 
has a bulk buying scheme directed tewards purchases ef 
gener,ic items, then retention ef brands fer experts. is 
impessible (save to. industrialised ceuntries which may 
retain brands). In these cases where brarided experts 
are allewed and are feasible (frem a develeping ceuntry 
which, like India, has preduc'tien facilities lecated in 
itsterritery) the ebject should be to. build up a repu-
tatien fer genuinely demestic cempanies, net fer affili-
ates of transnational corporatiens. The reputatien will 
be accentuated net by trademarks but by the cempetitive 
perfermance of the preducts. 
(9) Effe,cts on Growth: To build up a pharmaceutical in-
dustry is not an aim which has any meaning unless. clearly 
specified cenditiens are set eut. What is wanted, wher-
ever 'feasible, is access, in the right quantities, qual-
ities, places and times, to. those drugs which'are,the 
most useful, given prices and therapeutic effects, to. 
the health needs ef aceuntry. Demestic preductien must 
be established en that criterion and growth, in the sense 
ef greater eutput, is only helpful when it correspends 
to. those cenditiens., ' ' 
(10) Patent' Life: As neted earlier, whereas patents have 
a limited life, trademarks can be renewed indefinitely. 
The.twe combined give a perpetual legal pretectien which 
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must be removed~what has been said elsewhere in the 
study"emphas:i:ses the ""importance" "of· eliminating; this·· 
source of market power. 
The Indian policy experience is' a valuable one, com-
ing as it does from the largest developing country pro-
ducerofpharmaceuticals in which a major part of pro-
duction is in the hands of transnational companies. 
Thorough investigations of the industry have combined. to 
give all the recommendations which, if "implemerited, 
would dramatically alter the face' of the industry. Nu,-" 
merous problems remain, however, and 'the stakes are so 
big that one can depend on the resources available with 
the multinationals to resist any attempt to touch brand 
names. '60 
(iii) B:r>aziZ 
In 1971 a government body called the Central de Medica-
mentos {CEMEl was established with the objective of pro-
viding medicines to" the poorer parts of the population 
at very low or zero cost. A basic lrst of 400 medica-
ments was drawn up on the basis of which most ·of the 
country's chemically treatable health problems could be 
met. The list formed part of a Master Plan which inclu-
ded tight controls on the sale and promotion of drugs, 
regulations on the content of package inserts {the leaf-
lets supposed to describe what the drug does or does not 
doland restrictions on the distribution of free samples. 
By end 1973 CEME was dealing with 108 pharmaceutical pro-
ducts of which 52 ~lere classified as essentiaL 61 Items 
were purchased through' public bids with CEME specifying 
type, quantity and delivery dates. 'All purchases must" 
carry the CEME signet or seal, with the name ofthe'medi-
cine incorporating the name CE~m. The name of the actual 
manuf,~cturer does not appear on the package, aont:r>a:r>y to 
o:r>iginaZ expeatations of the indust:r>y whiahhad antiai-
pated some pubZiaity faZZout f:r>om the a:r>:r>angement. ,62 
In Brazil, as in the vast majority of developing 
countries, wholesale' pu'rchasing by the government: could 
not be effective without a major effort to alter the 
prescribing practices of phYSicians. Those connected 
with government health services, were expected to pre-" 
scribe to low-income patients whilst those in private 
practice were urged to prescribe to their low-income 
clients. As an aid to this CEME has engaged in promotion 
of products, albeit on a modest scale, through radio an-
nouncements in the north-east of the country ,.and has 
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sought to conduct promotional campaigns vis-a-vis the 
medical profession itself. The reaction of the companies 
to'these initiatives has been predictable enough. As the 
President of Pfizer's Brazilian subsidiary indicated: 
'We are prepared to co-operate with CEME, to provide the 
drugs at a 50 pel:' cent discount - in fact,we have some 
room for an increase in production - but we are only pre-
pared to do it as long as the government does not dis-
t,ribute the medicines to those who can buy them.' 63 
The division between the market for the poor, seen 
as an appendage by the companies, and the market for the 
middle classes and above was stated in a report by Busi-
ness Latin America at the end of 1973: 'Some executives 
feel that Brazil's rapidly growing middle class can af-
ford to pay for more specialised and sophisticated rem-
edies than those marketed by CEME. In other words, they 
are content to leave to CEME the job of developing a fu-
ture market among Brazil's poor: '64 _ 
A series of administrative ~hifts reflecting re-
evaluations of the I·laster Plan have t-aken place since it 
was announced and their effect has been to reduce dras-
tically the scope of action for CE~._Insofar as the 
purchasing decisions are concerned, the list of drugs, 
originally 400, was cut to 293 in July 1975 when the 
Minister of Welfare (under whose wing part of CEME's 
functions were now to be exercised after their removal 
from the Office of the Presidency) published a fresh list 
of medicines on which CE~m was supposed to focus atten-
tion. 'Certain essential drugs were no longer on the 
list, and, more'importantly, the list had been reduced 
toa mere guideline.: CEME, and other government insti-
tutions which might-distribute drugs to the poor, could, 
substitute for the drugs named on the list any similar 
drug on the market. '65 , 
Brazil is the second largest developing country pro-
ducer of pharmaceuticals and likewise has a dominant 
share of its market in the hands of transnationals. The 
proposals and initiatives 'taken there have also, thus 
far, failed to make a decisive breach in the pattern of 
production, marketing and distribution. The general pat-
tern of government action is clear yet successful radical 
movesh~ve still to be made. 
CONCLUDING REMARKS 
Whatever is done with regard to trademarks in the phar-




prime requirement, as is being increasingly recognised, 
is. the establishment and implementation· of a basic arug 
list drawn up in accordance with each country's health 
needs. Given such a list, purchasing procedures which 
ensure that imports are obtained as cheaply as possible 
subject to quality considerations are required for many 
if not most developing countries - for those where do-
mestic production can fill the require~ents, so much the 
better. Yet the existence of the right drugs is not by 
itself enough. Doctors must be informed about them and 
intensive information. diffusion must be undertaken by 
the public authoritiesl only then will prescribing hab-
its be altered. In this process the professional skills, 
currently idle, of the pharmacists should be mobilised 
·to the full. 
In this setting, and in view of the evidence set 
out in this article, there is a powerful case for the 
elimination, or at least restrictions of the grant of 
trademarks in the pharmaceutical sector in developing 
countries. This would represent a departure from the 
hitherto standard practice of accepting trademarks in 
all sectors without exception. Yet the pernicious ef-
fects of the brand name plague are abundantly clearl un-
less steps are taken rapidly,. it is hard to see how. the 
limitations. on patents in the sector, now fairly common 
in developing countries, can hope to bear fruit. For 
the export market, particularly to developed countries, 
some countries may wish to permit the trademarks to con-
tinue, irrespective of whether the exporting is done by 
a foreign or national enterprise. In the context of co-
operative arrangements among.developing countries, where 
there was jointly organised production to meet the needs 
of the participants, the use of a brand name would not 
serve' any purpose for intra-group supplies; if'the co-
operative wanted to export to third markets, a labelling 
device of some sort could then be used. . 
A final observation is needed. The·benefits from 
liquidating the brand name difficulties will not be rea-
lised unless the resources saved are genuinely put to 
work improving the totality of health services and thus 
.the health of the population. This must remain thecen-
tral objective not merely of trademark policy in the 
sector but of policies towards pharmaceuticals as a 
whole. 
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